Virpax Pharmaceuticals Inc Stock

$0.30

1.83% yesterday

Nasdaq, Jun 27, 05:43 pm CET

ISIN

US9282511073

Symbol

VRPX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Virpax Pharmaceuticals Inc Stock price

$0.32

-2,499.69 99.99% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.01 4.83%

ISIN

US9282511073

Symbol

VRPX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$390.0k

Enterprise Value

$-1.1m

Net debt

$-1.5m

Cash

$1.5m

Shares outstanding

14.9m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

0.07

P/B

negative

Financial Health

Equity Ratio

-58.74%

Return on Equity

1,320.55%

ROCE

1,327.47%

ROIC

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

- | -

EBIT

$-12.1m

Net Income

$-12.1m | $-235.4m

Free Cash Flow

$-16.7m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

- | -

EBIT

23.01%

Net Income

20.54% | -1,850.37%

Free Cash Flow

-69.64%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$-1.30

FCF per Share

$-1.12

Short interest

1.81%

Employees

7.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Virpax Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a Virpax Pharmaceuticals Inc forecast:

3x Hold

50%

3x Sell

50%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a Virpax Pharmaceuticals Inc forecast:

Hold

50%

Sell

50%

Analyst Estimates with Stock Price Targets

Financial data from Virpax Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	6.26 6.26	41% 41% -
- Research and Development Expense	5.82 5.82	14% 14% -
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-12 -12	23% 23% -
Net Profit	-12 -12	21% 21% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Virpax Pharmaceuticals Inc Stock News

Neutral

Business Wire

●

3 months ago

Virpax Pharmaceuticals Announces Reverse Stock Split

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, p...

Neutral

Business Wire

●

3 months ago

Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND

BERWYN, Penn.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced positive results from a beagle dog dose range finding (“DRF”) study. Probudur is the com...

Neutral

Business Wire

●

4 months ago

Virpax Looking to Use MET to Develop Intranasal COVID Vaccine

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is looking to use Molecular Envelope Technology (MET) or a similar technology to deliver a mRNA COVID vacc...

More Virpax Pharmaceuticals Inc News

Company Profile

Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Its products include metered-dose spray, liposomal gel encapsulates, and intranasal spray. The company was founded by Anthony P. Mack and Jeffrey A. Gudin in 2016 and and is headquartered in Berwyn, PA.

Head office	United States
CEO	Jay Dhaliwal
Employees	7
Founded	2016
Website	virpaxpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now